Pfizer Pharmaceuticals Korea conducts ‘Pneumococcal Prevention Number One (111) Campaign’ < Pharmaceutical/Bio < Text of article

In celebration of the 2024 World Immunization Week (April 24 to April 30), Pfizer Pharmaceuticals Korea (CEO Dong-wook Oh) ​​launched the ‘Pneumococcal Prevention Number One (Pneumococcal Prevention Number One) program to raise awareness of the dangers of pneumococcal disease and the importance of pneumococcal vaccine vaccination. 111) Campaign’ was announced on the 25th.

The World Health Organization (WHO) designated the last week of April every year as World Immunization Week to protect more people from vaccine-preventable diseases and to work with countries around the world to raise awareness of the value of vaccinations. Vaccination is a key element of primary health care and one of the best investments in health. According to WHO, vaccination saves 3.5 to 5 million people a year from diseases such as influenza, whooping cough and measles.

In commemoration of this year’s World Immunization Week, Pfizer Korea held an in-house event for executives and employees to raise interest and awareness of pneumococcal disease and to recall the importance of pneumococcal vaccination at all ages.

At this event, ▲ Pneumonia, the number one mortality rate among respiratory diseases in Korea ▲ Prevenar 13, the world’s number one selling pneumococcal vaccine (as of 2022) ▲ No. 1 pneumococcal vaccine in domestic sales for 14 consecutive years, focusing on the number ‘1’ in Prevenar 13 The ‘Pneumococcal Prevention Number One (111) Campaign’ was carried out. Through this campaign, Pfizer Korea announced the importance of pneumococcal vaccination to its employees and encouraged employees and their families who have not yet been vaccinated to get vaccinated.

In addition, as part of the campaign, the global pneumococcal serotype map was used to share information on the most frequent pneumococcal serotypes in major countries, including the invasive pneumococcal serotypes that frequently occur in Korea. In domestic children and adolescents, serotype 10A occurred most frequently, and in adults, serotypes 3 and 19A occurred most frequently.

Song Chan-woo, Vice President of Pfizer Korea’s Primary Care Division, said, “We held an event to raise awareness of the importance of pneumococcal vaccination with executives and employees who have worked to ensure a stable supply of pneumococcal vaccine and increase vaccination rates for the 14 years since it was approved in Korea. “It is meaningful to be able to proceed,” he said. “We will continue to do our best to ensure that people can protect not only themselves but their entire family’s health through pneumococcal vaccination.”

Meanwhile, Prevenar 13 has been introduced as a national immunization (NIP) for children in over 133 countries around the world (as of March 2024). Additionally, Pfizer Pharmaceuticals Korea has supplied approximately 13 million doses (2010-2023 4Q) of the vaccine domestically since Prevenar 13 was approved in 2010.

close